Related Experiment Video
Updated: Jun 19, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic
Roberta Ara1, Rachid Rafia, Sue E Ward
1School of Health & Related Research, University of Sheffield, Regent Court, Sheffield S1 4DA, UK. r.m.ara@sheffield.ac.uk
Insights
Intensive lipid-lowering therapy is cost-effective for acute coronary syndrome patients compared to standard statins. Atorvastatin 80 mg/day is optimal post-patent expiry, while simvastatin 80 mg/day is not recommended.
Area of Science:
- Cardiovascular Medicine
- Health Economics
- Pharmacoeconomics
Background:
- Acute coronary syndrome (ACS) necessitates effective and economical long-term management strategies.
- Lipid-lowering therapies are crucial in managing ACS, with varying cost-effectiveness profiles.
- Identifying optimal treatment regimens balances clinical outcomes with economic considerations.
Purpose of the Study:
- To review the literature on the cost-effectiveness of intensive lipid-lowering regimens versus generic low-dose statins in ACS patients.
- To compare the economic value of different statin treatment intensities for secondary prevention post-ACS.
- To determine the most cost-effective statin therapy based on projected long-term outcomes and costs.
Main Methods:
- A literature review was performed to identify relevant cost-effectiveness studies.
- Included studies utilized Markov models to simulate long-term clinical pathways and costs.
- Studies were analyzed for differences in effectiveness data, health state definitions, and predicted events.
Main Results:
- All reviewed studies concluded that intensive lipid-lowering regimens are cost-effective compared to generic low-dose statins for ACS.
- Significant variations existed in effectiveness data, health state definitions, and event predictions across studies.
- Atorvastatin 80 mg/day is projected as the most optimal treatment if its annual cost decreases to GBP 90 post-patent expiry.
Conclusions:
- Intensive lipid-lowering therapy offers a cost-effective strategy for managing patients with acute coronary syndrome.
- Atorvastatin 80 mg/day emerges as the preferred optimal treatment option for ACS patients following patent expiry, given its favorable cost-effectiveness.
- Simvastatin 80 mg/day is not recommended due to safety concerns and limited additional benefits compared to intensive regimens.
Abstract:
A literature review was conducted to identify studies exploring the cost-effectiveness of intensive lipid-lowering regimens compared with a generic low-dose statin for individuals with acute coronary syndrome. Three papers matched the inclusion criteria. All used a Markov model to represent the long-term clinical pathway; two were set in the UK and one was in the USA. While there were substantial differences in the effectiveness data, the definitions of the health states and the numbers of events predicted, all authors found that the intensive regimen was a cost-effective alternative compared with a generic lower dose statin. If the cost of atorvastatin reduces from GBP 368 pounds to 90 pounds per annum when the patent expires in 2011, atorvastatin 80 mg/day would be the most optimal treatment for this patient group. Simvastatin 80 mg/day should not be considered an alternative owing to an adverse safety profile and limited additional benefits.
Related Concept Videos
Atherosclerosis III: Management
Acute Coronary Syndrome IV: Interprofessional Care
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Acute Coronary Syndrome V: Nursing Management
Acute Coronary Syndrome III: Diagnostic Studies
Atherosclerosis IV: Nursing Management